Crispr Therapeutics ((CRSP)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The study titled A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies aims to assess the long-term safety and efficacy of CRISPR CAR T cellular therapies. This observational study is significant as it seeks to gather data on the long-term outcomes of patients with hematological and solid malignancies who have undergone these innovative treatments.
Intervention/Treatment: The intervention being tested is a non-interventional follow-up of patients who have received allogeneic CRISPR CAR T cellular therapy. The primary purpose is to monitor safety and efficacy over an extended period.
Study Design: This is an observational cohort study with a prospective time perspective. It involves participants from a parent study who have been treated with CRISPR CAR T therapies, focusing on long-term data collection.
Study Timeline: The study began on November 22, 2023, with an estimated completion date not specified. The primary completion date is yet to be determined, and the latest update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipated findings.
Market Implications: This update from Crispr Therapeutics could influence its stock performance positively by reinforcing investor confidence in the potential of CRISPR CAR T therapies. As the biotech industry closely watches advancements in gene editing, successful long-term results could position Crispr Therapeutics favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.